Featuring perspectives from Dr Matthew D Galsky, including the following topics:

HER2 alterations in urothelial cancer and current targeting approaches (0:00)
Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39)
Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31)
Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57)
Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25)
Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34)
Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48)

Laura Gentile on Building A Winning Brand at ESPN